Kinase Assay Platform Expanded to Address Tyrosine Enzymes

The original platform consists of four kits combining three biotinylated substrates, S1, S2 and S3, with a monoclonal antibody and HTRF. Since the new Tyr kinase assay is based on the same monoclonal antibody principle as HTRF KinEASE, the implementation of the assay by HTRF KinEASE users is very straightforward.

Cisbio International (Bagnols-sur-Cèze, France) announced the launch of HTRF KinEASE TK at the Society for Biomolecular Screening (SBS) Conference in Montreal, Canada, on April 15, 2007. With the development of this new tool, Cisbio now offers its customers the ability to use a reliable and sensitive kinase-screening platform based on one technology to address a broad range of kinase targets.

KinEASE TK combines a peptide substrate called S4 and a single, proprietary monoclonal antibody with Cisbio's HTRF technology, a highly sensitive, robust technology for the detection of molecular interactions of proteins in vitro. HTRF KinEASE TK limits assay development time and is easily miniaturizable and flexible, meaning that the assay can be performed under a wide range of kinase assay conditions, for example, with low consumption of enzyme or with any adenotriphosphate (ATP) concentration. HTRF KinEASE TK is the fifth kit in the HTRF KinEASE platform, developed in collaboration with Millipore (Upstate; Charlottesville, VA, USA) for profiling and high-throughput system (HTS) analysis of serine/threonine (Ser/Thr) kinases.

The company also produces a selection of biologic reagents and methods used by pharmaceutical and biotechnology companies, as well as contract research organizations (CROs). Cisbio international has facilities in France and the United States, and sales offices in Japan and India.


Related Links:
Cisbio International
Millipore (Upstate)